Skip to contentE
Emergent BioSolutions Inc.
E
EBSEmergent BioSolutions Inc. Q1 2016 · 10-Q
Revenue$111.00M$111.00M+74.4% vs Q1 2015 Net Income$3.99M$3.99MN/M vs Q1 2015 EPS Diluted$0.10$0.10N/M vs Q1 2015 Gross Profit$21,157,000N/M Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
Operating Cash Flow$42,171,000N/M Free Cash Flowderived$23,957,000N/M Margins · derivedGross margin19.1%+53.5 pt vs Q1 2015
Operating margin19.1%+63.5 pt vs Q1 2015
Net margin3.6%+37.4 pt vs Q1 2015
ended Mar 31, 2016 · filed May 6, 2016 · 36 d after period end